TY - JOUR
T1 - The effect of vitamin E addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in schizophrenic patients
T2 - An open label study
AU - Dorfman-Etrog, Pnina
AU - Hermesh, Haggai
AU - Prilipko, Leonid
AU - Weizman, Abraham
AU - Munitz, Hanan
N1 - Funding Information:
This study was supported by the Sarah and Moshe Mayer Foundation for Research (Tel Aviv and Geneva, Switzerland) and the Golden Gate Foundation (London, UK). We are grateful to Mrs. Gloria Ginzach and Mrs. Charlotte Sachs of the Editorial Board, Rabin Medical Center, Beilinson Campus, for their assistance.
PY - 1999/12
Y1 - 1999/12
N2 - The anti-oxidant vitamin E has been reported to be effective in the treatment of tardive dyskinesia. The present open label study examined the effect of supplemental therapy with vitamin E on acute extrapyramidal symptoms and cell enzymes in patients receiving neuroleptic drugs. Thirty- nine hospitalized schizophrenic patients were randomly assigned to two groups: group 1 (n=20) was treated with neuroleptics, and group 2 (n=19) with neuroleptics combined with a fixed dose of vitamin E (600 IU/day), administered for two weeks. All patients were assessed with the Simpson-Angus Rating Scale (Simpson and Angus, 1970) for neuroleptic induced Parkinsonism (NIP), Barnes' Akathisia Scale (Barnes, 1989), and Brief Psychiatric Rating Scale: laboratory parameters included serum creatine kinase (CK) activity, serum glutamate oxaloacetic transaminase (SGOT) and white blood cell count (WBC). The addition of vitamin E to neuroleptic agents was associated with a trend (p=0.08) towards prevention of the emergence of NIP compared to neuroleptic treatment alone. Addition of vitamin E to neuroleptics may reduce the severity of acute NIP in schizophrenic patients. (C) 1999 Published by Elsevier Science B.V.
AB - The anti-oxidant vitamin E has been reported to be effective in the treatment of tardive dyskinesia. The present open label study examined the effect of supplemental therapy with vitamin E on acute extrapyramidal symptoms and cell enzymes in patients receiving neuroleptic drugs. Thirty- nine hospitalized schizophrenic patients were randomly assigned to two groups: group 1 (n=20) was treated with neuroleptics, and group 2 (n=19) with neuroleptics combined with a fixed dose of vitamin E (600 IU/day), administered for two weeks. All patients were assessed with the Simpson-Angus Rating Scale (Simpson and Angus, 1970) for neuroleptic induced Parkinsonism (NIP), Barnes' Akathisia Scale (Barnes, 1989), and Brief Psychiatric Rating Scale: laboratory parameters included serum creatine kinase (CK) activity, serum glutamate oxaloacetic transaminase (SGOT) and white blood cell count (WBC). The addition of vitamin E to neuroleptic agents was associated with a trend (p=0.08) towards prevention of the emergence of NIP compared to neuroleptic treatment alone. Addition of vitamin E to neuroleptics may reduce the severity of acute NIP in schizophrenic patients. (C) 1999 Published by Elsevier Science B.V.
KW - Akathisia
KW - Creatine kinase
KW - Extrapyramidal side effects
KW - Neuroleptics
KW - Oxidation
KW - Parkinsonism
KW - Schizophrenia
KW - Vitamin E
UR - http://www.scopus.com/inward/record.url?scp=0033367353&partnerID=8YFLogxK
U2 - 10.1016/S0924-977X(99)00015-2
DO - 10.1016/S0924-977X(99)00015-2
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.editorial???
AN - SCOPUS:0033367353
SN - 0924-977X
VL - 9
SP - 475
EP - 477
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
IS - 6
ER -